Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Prepaid Assets (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Prepaid Assets for 16 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Prepaid Assets fell 6.82% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, down 6.82% year-over-year, with the annual reading at $1.3 million for FY2025, 6.82% down from the prior year.
  • Prepaid Assets for Q4 2025 was $1.3 million at Gyre Therapeutics, down from $2.9 million in the prior quarter.
  • The five-year high for Prepaid Assets was $8.5 million in Q1 2021, with the low at $377000.0 in Q4 2022.
  • Average Prepaid Assets over 5 years is $2.9 million, with a median of $1.6 million recorded in 2024.
  • The sharpest move saw Prepaid Assets tumbled 89.03% in 2022, then skyrocketed 355.92% in 2025.
  • Over 5 years, Prepaid Assets stood at $2.8 million in 2021, then tumbled by 86.57% to $377000.0 in 2022, then surged by 177.19% to $1.0 million in 2023, then soared by 37.42% to $1.4 million in 2024, then decreased by 6.82% to $1.3 million in 2025.
  • According to Business Quant data, Prepaid Assets over the past three periods came in at $1.3 million, $2.9 million, and $2.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.